Medications for Dermatitis Atopic

128 results

  • Adbry

    (tralokinumab-ldrm)
    LEO Pharma Inc.
    Usage: ADBRY is indicated for treating moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and older when topical therapies are ineffective or unsuitable. It may be used with or without topical corticosteroids.

  • Aloquin (aloe vera leaf and iodoquinol)

    (Aloe Vera Leaf and Iodoquinol)
    Primus Pharmaceuticals
    Usage: This drug is indicated for potentially effective treatment of various dermatological conditions including contact dermatitis, atopic dermatitis, eczema types, stasis dermatitis, pyoderma, acne urticata, neurodermatitis, lichen simplex, anogenital pruritus, folliculitis, and certain fungal infections. Further research is needed for definitive classification of some uses.

  • Baycadron (dexamethasone)

    (Dexamethasone)
    Wockhardt USA, LLC
    Usage: This drug is indicated for various conditions, including endocrine disorders (e.g., adrenal insufficiency), rheumatic disorders (e.g., arthritis), collagen diseases, dermatologic diseases, severe allergic reactions, ophthalmic inflammation, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and special cases like tuberculous meningitis and trichinosis.

  • Beta 1 kit (betamethasone sodium phosphate, betamethasone acetate)

    (Betamethasone Sodium Phosphate, Betamethasone Acetate)
    Oaklock, LLC
    Usage: Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for severe allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neurologic conditions, and various inflammatory diseases. It serves as adjunctive therapy for specific acute episodes and can be used intramuscularly, intra-articularly, or intralesionally.

  • Cibinqo

    (abrocitinib)
    U.S. Pharmaceuticals
    Usage: CIBINQO is indicated for adults and patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis inadequately controlled by other systemic therapies. It is not recommended for use with other JAK inhibitors, biologics, or immunosuppressants.

  • Cibinqo (abrocitinib)

    (abrocitinib)
    Pfizer Laboratories Div Pfizer Inc
    Usage: CIBINQO is indicated for treating adults and pediatric patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis not adequately controlled by other systemic treatments, including biologics, or when those therapies are inadvisable. It is not recommended for use with other JAK inhibitors or immunosuppressants.

  • Derma-smoothe/fs (fluocinolone acetonide)

    (fluocinolone acetonide)
    Royal Pharmaceuticals
    Usage: Derma-Smoothe/FS® is indicated for the topical treatment of atopic dermatitis in adult patients and moderate to severe atopic dermatitis in pediatric patients aged 3 months and older for up to 4 weeks. Limitations include avoiding occlusive areas and discontinuation once disease control is achieved.

  • Desonate (desonide)

    (desonide)
    Intendis Inc.
    Usage: Desonate is indicated for the treatment of mild to moderate atopic dermatitis in patients aged 3 months and older. It should be used for the shortest time necessary, not exceeding 4 consecutive weeks, due to potential HPA axis suppression.

  • Desonate™ (desonide) gel 0.05% (desonide)

    (desonide)
    SkinMedica
    Usage: Desonate Gel is indicated for treating mild to moderate atopic dermatitis in patients aged 3 months and older. It should be used for the shortest time necessary, not exceeding 4 consecutive weeks, due to the risk of HPA axis suppression.

  • Desonide (desonide)

    (Desonide)
    Cintex Services, LLC
    Usage: Desonide Gel, 0.05% is indicated for treating mild to moderate atopic dermatitis in patients aged 3 months and older. It should be used for the shortest duration necessary to achieve results, not exceeding 4 consecutive weeks, due to potential HPA axis suppression.